Company: MBIO
Filing Date: 2025-04-04
Form Type: POS AM
Source: 0001104659-25-032236
Chunk: 17

Company: MUSTANG BIO, INC.
Filing Date: 2025-04-04
Form: POS AM
Chunk 17
---
.00 per share
(subject to adjustment as set forth in the warrants), were exercisable immediately upon issuance and will expire five and one-half (5.5) years
thereafter. The warrants contain standard anti-dilution adjustments to the exercise price including for share splits, share dividend,
rights offerings and pro rata distributions. This private placement closed on October 30, 2023, concurrently with an offering to
the same institutional accredited investor that was registered under the Securities Act. The gross proceeds to us from the private placement,
before deducting placement agent fees and other estimated offering expenses payable by the Company, were approximately $0.32 million.
H.C. Wainwright & Co., LLC (“Wainwright”) acted as the exclusive placement agent in connection with the private placement
under an engagement, between the Company and Wainwright. Pursuant to the Engagement Letter, Wainwright was paid a cash fee equal to 7.0%
of the gross proceeds received by us in the Offerings, a management fee equal to 1.0% of the gross proceeds of the Offering, $75,000 for
non-accountable expenses and a clearing fee of $15,950. In addition, under the terms of the Engagement Letter, we issued to Wainwright
(or its designees) warrants to purchase up to 3,104 shares of Common Stock (the “Wainwright Warrants”). The Wainwright Warrants
have substantially the same terms as the Warrants, except that the Wainwright Warrants will expire five (5) years from the commencement
of the sales of the Offerings and have an exercise price of $106.25 per share (subject to customary adjustment as set forth in the Wainwright
Warrants). The 2023 Warrants were offered and sold in reliance on the exemption from registration provided by Section 4(a)(2) of
the Securities Act. The investor also represented that it qualified as an “accredited investor” within the meaning of Rule 501
of Regulation D.

<div align='center'>19</div>

June 2024 Private Placement

On June 19, 2024, we entered into a purchase
agreement (the “June 2024 Purchase Agreement”) with an institutional accredited investor, for the issuance and sale of
warrants (the “June 2024 Warrants”) to purchase up to 122,600 shares of our common stock. Pursuant to the June 2024
Purchase